LifeMD, Inc. (NASDAQ:LFMD) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of LifeMD, Inc. (NASDAQ:LFMD) have earned a consensus rating of “Moderate Buy” from the nine analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $9.1429.

Several research analysts recently issued reports on the company. Loop Capital set a $10.00 price objective on LifeMD in a research note on Thursday, March 12th. Mizuho raised LifeMD from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $6.00 to $8.00 in a research note on Monday, March 16th. Weiss Ratings raised LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research note on Thursday. Wall Street Zen lowered LifeMD from a “hold” rating to a “sell” rating in a report on Saturday. Finally, BTIG Research reaffirmed a “buy” rating and set a $10.00 target price on shares of LifeMD in a research report on Monday, May 4th.

LifeMD Price Performance

Shares of NASDAQ:LFMD opened at $4.78 on Wednesday. LifeMD has a 52-week low of $2.56 and a 52-week high of $15.84. The stock has a market cap of $231.16 million, a P/E ratio of 95.62 and a beta of 2.03. The business’s 50 day moving average is $3.87 and its 200 day moving average is $3.93.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06). LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%.The firm had revenue of $50.16 million during the quarter, compared to the consensus estimate of $48.84 million. On average, sell-side analysts anticipate that LifeMD will post 0.01 EPS for the current fiscal year.

Institutional Trading of LifeMD

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in LifeMD by 6.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,226,871 shares of the company’s stock valued at $15,120,000 after acquiring an additional 140,749 shares in the last quarter. Federated Hermes Inc. boosted its position in LifeMD by 278.1% during the 4th quarter. Federated Hermes Inc. now owns 980,285 shares of the company’s stock valued at $3,343,000 after acquiring an additional 721,018 shares in the last quarter. Geode Capital Management LLC boosted its position in LifeMD by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 959,700 shares of the company’s stock valued at $3,273,000 after acquiring an additional 11,324 shares in the last quarter. Royce & Associates LP boosted its position in LifeMD by 11.7% during the 4th quarter. Royce & Associates LP now owns 909,651 shares of the company’s stock valued at $3,102,000 after acquiring an additional 95,200 shares in the last quarter. Finally, Whetstone Capital Advisors LLC boosted its position in LifeMD by 89.6% during the 4th quarter. Whetstone Capital Advisors LLC now owns 703,053 shares of the company’s stock valued at $2,397,000 after acquiring an additional 332,269 shares in the last quarter. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.